Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury
Mark R. Looney, … , Clifford A. Lowell, Michael A. Matthay
Mark R. Looney, … , Clifford A. Lowell, Michael A. Matthay
Published October 5, 2009
Citation Information: J Clin Invest. 2009;119(11):3450-3461. https://doi.org/10.1172/JCI38432.
View: Text | PDF
Research Article Pulmonology

Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury

  • Text
  • PDF
Abstract

Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-associated mortality in the US. Previously, we established an immune-mediated TRALI mouse model, wherein mice with cognate antigen were challenged with MHC class I mAb. In this study, when mice housed in a rodent, specific pathogen–free barrier room were challenged with MHC I mAb, there was significant protection from TRALI compared with nonbarrier mice. Priming mice with LPS restored lung injury with mAb challenge. Using TLR4-deficient bone marrow chimeras, the priming phenotype was restricted to animals with WT hematopoietic cells, and depletion of either neutrophils or platelets was protective. Both neutrophils and platelets were sequestered in the lungs of mice with TRALI, and retention of platelets was neutrophil dependent. Interestingly, treatment with aspirin prevented lung injury and mortality, but blocking the P selectin or CD11b/CD18 pathways did not. These data suggest a 2-step mechanism of TRALI: priming of hematopoietic cells, followed by vascular deposition of activated neutrophils and platelets that then mediate the severe lung injury. Furthermore, our data offer an explanation for the increased incidence of TRALI in patients with immune priming conditions, and we suggest what we believe to be a novel therapeutic approach.

Authors

Mark R. Looney, John X. Nguyen, Yongmei Hu, Jessica A. Van Ziffle, Clifford A. Lowell, Michael A. Matthay

×

Figure 2

Priming with i.p. LPS restores lung injury after MHC I mAb challenge.

Options: View larger image (or click on image) Download as PowerPoint
Priming with i.p. LPS restores lung injury after MHC I mAb challenge.
(A...
(A and B) Extravascular lung water and EVPEs in barrier mice administered i.p. LPS (0.1 mg/kg) with and without increasing doses of MHC I mAb. **P < 0.05 vs. 0 mg/kg H2Kd mAb; †P < 0.05 vs. 0.5, 1.0, 2.25, and 4.5 mg/kg H2Kd mAb. (C) Survival curves from mice in A and B. P = 0.02 (Fisher’s exact) for trend of increasing mortality, with increasing dose of MHC I mAb.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts